Drugs / VT1021
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03364400 | Nov 2017 → Jan 2024 | cancer | Vigeo Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03970447 ↗ |
| Action | Activate | “induces the expression of thrombospondin-1 (TSP-1)” PMID 38218979 ↗ Jan 2024 |
| Modality | Peptide | “VT1021 is a cyclic peptide” PMID 38218979 ↗ Jan 2024 |
| Route | Intravenous | “dosed twice weekly intravenously” PMID 38218979 ↗ Jan 2024 |